December 5, 2016 08:33 AM EST
R&D

Cere­cor blast­ed as its sec­ond clin­i­cal roll of the dice in days comes up snake eyes

John Carroll

Editor & Founder

Just a few days af­ter Cere­cor was pum­meled $CERC by the news that its lead de­pres­sion drug, CERC-301, failed a mid-stage study, the mi­cro­cap …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

A new dawn for psy­che­delics? Com­pass could be the first to find out

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times